What is the percentage of tricyclic antidepressant (TCA) for a TA cross?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

TCA Dose Reduction for CYP2D6 Intermediate Metabolizers

For CYP2D6 intermediate metabolizers (IM) receiving tricyclic antidepressants, reduce the starting dose by 25% according to CPIC guidelines 1.

Pharmacogenetic Dosing Recommendations

The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides standardized dosing adjustments for TCAs based on CYP2D6 metabolizer status:

CYP2D6 Intermediate Metabolizers (IM)

  • Dose reduction: 25% of standard starting dose 1
  • This applies to amitriptyline, clomipramine, doxepin, imipramine, and trimipramine
  • Utilize therapeutic drug monitoring to guide subsequent dose adjustments 1

CYP2D6 Ultra-Rapid Metabolizers (UM)

  • Avoid TCAs due to potential lack of efficacy 1
  • If TCA use is warranted, consider titrating to higher target doses (125-200% depending on specific TCA) 1
  • Alternative: select drugs not metabolized by CYP2D6

CYP2D6 Poor Metabolizers (PM)

  • Avoid TCAs entirely 1
  • Consider alternative antidepressants not primarily metabolized by CYP2D6 (e.g., desipramine) 1

Important Clinical Considerations

Common pitfall: The Dutch Pharmacogenetics Working Group (DPWG) provides more specific, PK-based dosing for ultra-rapid metabolizers with different percentages for each TCA (amitriptyline 125%, clomipramine 150%, doxepin 200%, imipramine 170%, nortriptyline 160%), while CPIC recommends avoiding TCAs in this population 1. The CPIC recommendation to avoid is more conservative and prioritizes safety.

CYP2C19 considerations: For imipramine specifically, CYP2C19 poor metabolizers should receive a 30% dose reduction, while intermediate metabolizers should consider alternative drugs 2. Amitriptyline also has CYP2C19 interactions requiring dose adjustments 1.

Always implement therapeutic drug monitoring regardless of genotype-guided dosing, as individual patient factors beyond pharmacogenetics influence TCA metabolism and response 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.